UNSPSC 51422120: Mometasone furoate

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H30Cl2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04201GDN4R, chemically known as 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) but more generally known as mometasone furoate, which bears US NIH Compound Identifier 55188. European Medicines Agency schedules Mometasone furoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03318MIG.

UNSPSC 51422120 Mometasone furoate is a Commodity code that in practice reflects state and local government procurement of pharmaceutical products and related health supplies rather than the specific active ingredient named in the code's title. Recent solicitations under this code show state and local bodies purchasing naloxone, safe drug deactivation systems, and direct-to-manufacturer prescription fulfillment capabilities as part of broader community health and pharmacy benefit initiatives. Issuing bodies include county health departments (Seminole County, Florida) and state health and human services commissions (Texas Health and Human Services Commission), indicating that this code captures purchasing by both local public-health entities and state-level pharmacy benefit administrators. The scope of work spans both commodity procurement—fixed quantities of naloxone and drug-deactivation equipment delivered on a recurring schedule—and strategic pharmacy contracting, where states explore direct relationships with manufacturers to optimize prescription fulfillment and cost management outside traditional pharmacy benefit manager channels.

Geographic activity centers on Florida and Texas, the two states represented in recent postings. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, as a competitive sealed bid through the county's e-Procurement Portal; the contract includes a two-year initial term with an option for one-year renewal and is potentially FEMA-funded. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as an exploratory market-intelligence solicitation seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with responses due April 3, 2026; this RFI does not establish a binding contract timeline or budget but signals state intent to develop formal procurement specifications for direct pharmaceutical manufacturer contracting in subsequent phases. Both opportunities require vendors to meet federal compliance standards, including E-Verify employment verification and adherence to federal environmental regulations.